Brief: Tonix Pharmaceuticals Provides Update On The Development Of Its Single Dose Live Attenuated Virus Vaccine Candidate For Mpox

Tonix Pharmaceuticals Holding

16/08/2024 12:03

Aug 16 (Reuters) - Tonix Pharmaceuticals Holding Corp
 TNXP.O :
    * TONIX PHARMACEUTICALS PROVIDES UPDATE ON THE DEVELOPMENT
OF ITS
SINGLE DOSE LIVE ATTENUATED VIRUS VACCINE CANDIDATE FOR MPOX,
TNX-801, AS WHO DECLARES MPOX OUTBREAK A GLOBAL HEALTH EMERGENCY
    * TONIX PHARMACEUTICALS: TNX-801 VACCINATION DEMONSTRATED
EFFICACY
IN PROTECTING ANIMALS FROM LETHAL CHALLENGE WITH INTRATRACHEAL
MONKEYPOX VIRUS
    * TONIX PHARMACEUTICALS HOLDING CORP: TONIX'S VACCINE
PLATFORM HAS
BEEN SELECTED BY NIH'S PROJECT NEXTGEN FOR CLINICAL TESTING

Source text for Eikon:  ID:nGNXYNb5W 
Further company coverage:  TNXP.O 

 (Reuters.Briefs@thomsonreuters.com)